BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy

NCT05116774 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG: Eculizumab
DRUG: Ravulizumab
DRUG: BCX9930

Sponsor

BioCryst Pharmaceuticals